Our research in Immunology

Rheumatology

Gastroenterology

Dermatology

Neurology

Over 20 years ago, Bristol Myers Squibb pioneered the science of modulating the body’s immune response to treat disease, beginning with the company’s research in rheumatoid arthritis (RA). Building on that foundation, we continue to pursue pathbreaking science across rheumatic diseases including RA, psoriatic arthritis, lupus and ankylosing spondylitis. Fueled by the possibility to help more patients, we are following the science to tailor therapies to individual needs, improve outcomes and expand treatment options.

The American College of Rheumatology (ACR) Convergence 2022 meeting represents an important opportunity to review and share the latest research for people living with immune-mediated rheumatic diseases. We are looking forward to sharing 17 company-sponsored presentations, including clinical and health economics and outcomes research data across systemic lupus erythematosus, psoriatic arthritis and rheumatoid arthritis that further showcase the strength and depth of our robust portfolio. Together, our data continue to demonstrate our commitment to pursuing innovative science to address unmet needs for the rheumatology community.

Back to top

Bristol Myers Squibb is pursuing innovative research to potentially change the course of gastrointestinal immune-mediated diseases, including inflammatory bowel disease (IBD) (which includes ulcerative colitis and Crohn's disease) and eosinophilic esophagitis (EoE). Our scientific innovations have the potential to provide relief and remission to people living with these conditions.

The American College of Gastroenterology (ACG) 2022 annual meeting, taking place from October 21-26, is an important opportunity to showcase the latest advances in gastrointestinal research. Bristol Myers Squibb will be presenting 12 company-sponsored abstracts expanding on clinical data that demonstrate our commitment to addressing unmet needs for patients living with gastrointestinal immune-mediated diseases.

Back to top

Through Bristol Myers Squibb’s pioneering exploration of immune pathways implicated in dermatologic conditions, our discovery team’s research is leading to the potential for safe, effective, category-defining new therapies that may address the pressing treatment gaps that continue to exist for people living with these conditions. With a highly focused pipeline, we are pursuing novel treatments for psoriasis and atopic dermatitis and exploring a broad range of serious dermatologic conditions in our early research.

The European Academy of Dermatology and Venereology (EADV) Congress serves as an important opportunity to engage in scientific exchange with the dermatology research and medical community, and Bristol Myers Squibb looks forward to presenting 26 abstracts at this year’s meeting. This research reinforces the company’s unwavering commitment to pursuing pathbreaking science, with the goal of elevating care for people living with serious immune-mediated diseases, like psoriasis.  

Back to top

At Bristol Myers Squibb, we are focused on delivering solutions that may help preserve physical and cognitive function in people living with neurological conditions like multiple sclerosis (MS). Building on our experience, we are pursuing pathbreaking science to improve care for those impacted by the disease. By helping restore some of what MS has taken away, we aim to empower people living with MS and their loved ones to take back control of their lives. 

The Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022 represents an important opportunity for scientific exchange which can benefit patients and the neurology research community. Bristol Myers Squibb looks forward to sharing 13 company-sponsored presentations at this year’s meeting. The presentations demonstrate our commitment to advancing pathbreaking science for individuals living with relapsing forms of multiple sclerosis and other serious immune-mediated diseases.